Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2006 Jun 1;16(11):3055-60. Epub 2006 Mar 10.

SAR studies: designing potent and selective LXR agonists.

Author information

1
Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., Inc., PO Box 2000, Rahway, NJ 07065, USA. jason_szewczyk@merck.com

Abstract

Counterscreening compounds from a Merck PPAR program discovered lead 1, as a nanomolar LXR/PPAR dual agonist. SAR optimization developed a series of heterocyclic LXR agonists having excellent selectivity over all PPAR isoforms and possessing high LXR affinity and strong in vivo potency.

PMID:
16529931
DOI:
10.1016/j.bmcl.2006.02.050
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center